Get the latest market trends in your inbox

Stay on top of the latest market trends and economic insights with the Axios Markets newsletter. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Denver news in your inbox

Catch up on the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Des Moines news in your inbox

Catch up on the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Minneapolis-St. Paul news in your inbox

Catch up on the most important stories affecting your hometown with Axios Minneapolis-St. Paul

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tampa-St. Petersburg news in your inbox

Catch up on the most important stories affecting your hometown with Axios Tampa-St. Petersburg

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Amgen, Eli Lilly, Merck and the Association of National Advertisers are suing the Trump administration over its rule forcing pharmaceutical companies to display drugs' list prices in TV commercials.

Context: They say the rule violates the First Amendment and exceeds the government's authority.

The big picture: Experts expected drugmakers to file such a lawsuit — even though the new regulation isn't expected to actually affect drug pricing.

What they're saying: The drug companies argue in their complaint that the rule would have a "misleading effect," because the sticker prices would not represent what patients themselves have to pay.

  • The companies also say the regulation violates their First Amendment rights.
  • Amgen said the rule would not address what most patients want to know: what their out-of-pocket costs will be.

Between the lines: The rule itself is pretty small potatoes, but the lawsuit shows the self-interested goals of each party.

  • The Trump administration likes the rule because it's a talking point to say they are doing something about drug prices, despite federal officials admitting it would have negligible effects on patients and drug spending.
  • Pharmaceutical manufacturers don't like the rule because it might discourage patients from buying their products. Instead, the companies like to promote how insured patients can get their drugs for free or at a low cost through drug copay cards — which economists agree raise costs and allow drugmakers to charge higher prices.

Go deeper: New rule on drug prices is asking for lawsuits — literally

Go deeper

Updated 51 mins ago - Politics & Policy

Coronavirus dashboard

Illustration: Aïda Amer/Axios

  1. Politics: Fauci says he accepted Biden's offer to be chief medical adviser "on the spot" — The recovery needs rocket fuel.
  2. Economy: U.S. economy adds 245,000 jobs in November as recovery slows — America's hidden depression: K-shaped recovery threatens Biden administration.
  3. Education: Devos extends federal student loan relief to Jan. 31
  4. States: New Mexico to allow hospitals to ration coronavirus medical care
  5. Vaccine: What vaccine trials still need to do.
  6. World: UN warns "2021 is literally going to be catastrophic"
  7. 🎧 Podcast: Former FDA chief Rob Califf on the vaccine approval process.
2 hours ago - Health

A safe, sane survival guide

Photo: Luka Dakskobler/SOPA Images/LightRocket via Getty Images

We all know, it’s getting worse.

Reality check: Here are a few things every one of us can do to stay safe and sane in coming months:

Biden's debut nightmare

President-elect Biden speaks in Wilmington on Nov. 24. Photo: Chandan Khanna/AFP via Getty Images

A dim, gloomy scene seems increasingly set for Joe Biden's debut as president.

The state of play: He'll address — virtually — a virus-weary nation, with record-high daily coronavirus deaths, a flu season near its peak, restaurants and small businesses shuttered by wintertime sickness and spread.